5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6 -dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins.
1. The compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H-one monosodium salt hydrate thereof.
2. The compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H-one meglumine salt hydrate thereof in a crystalline form.
3. The compound of claim 1 wherein the compound is the monosodium salt.
4. The compound of claim 1 wherein the compound is a hydrate of the monosodium salt.
5. The compound of claim 4 wherein the hydrate contains less than 5.25 waters of solvation.
6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.